Yayoi Kusama: Infinity Rooms at London’s Tate Modern 2021

To celebrate the Tate Modern's 20th anniversary (a little late due to the pandemic), an exhibition dedicated to famed Japanese artist Yayoi Kusama will show her Infinity Rooms exhibition for a full year. This is rare chance to see two of Kusama's immersive mirror room installations, paired with photos and footage of her...

Covid-19’s digital imperative for biopharma and medtech

therapeutics
The public health crisis of Covid-19 continues to cast a long shadow on business operations everywhere, including the biopharma industry. It is preventing sales reps from visiting doctors, delaying product launches and making them more complex to execute. It is also impacting clinical trials and underscoring the need for a more digital focused...

Using digital engagement to solve pain points along the patient journey: How to deliver better outcomes for patients and brands

There are numerous challenges that a patient commonly faces along the patient journey, starting with the provider’s decision to treat and the course of therapy prescribed for the patient. Be a part of this webinar on November 10th at 1pm ET/10am PT  and learn to examine how digital engagement can solve challenges for both...

Landmark FDA approval of antiviral drug as 1st COVID-19 treatment comes amid conflicting efficacy data

Red seal and imprint "FDA APPROVED" on white surface. FDA - Food and Drug Administration is a federal agency of the United States Department of Health and Human Services.
The FDA has approved remdesivir for the treatment of Covid-19, making it the first and only treatment for the disease caused by the new coronavirus. The green light from the agency comes just one week after a WHO report found that the drug wasn’t that effective in patients hospitalized with the illness. Manufactured by...

Augmedix goes public through reverse merger

Medical documentation startup Augmedix went public through a reverse merger with Malo Holdings. A subsidiary of the company merged with Augmedix on October 5, allowing it to begin trading over-the-counter on OTCQB. After the merger, CEO Emmanuel Krakaris will continue in that role, and founder Ian Shakil will also continue to serve as Augmedix’s...